EC to purchase up to 160 mill doses of Moderna’s COVID-19 vaccine
Moderna announced today that the European Commission has approved an agreement to buy 80 million doses of mRNA-1273, Moderna’s COVID-19
Read more
vaccine development
Trial data shows AstraZeneca’s COVID-19 vaccine was highly effective
AstraZeneca announced today, that interim trial data has shown it’s COVID-19 vaccine candidate AZD1222, developed in collaboration with the University
Read more
Moderna’s COVID-19 vaccine shows efficacy of 94.5% in Phase 3 trial
Moderna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read more
CureVac’s COVID-19 Vaccine stable at standard refrigerator temperature
CureVac, a German biopharmaceutical company developing innovative medicines based on messenger ribonucleic acid (mRNA), announced that its mRNA-based COVID-19 vaccine
Read more
Pfizer and BioNTech announce important COVID-19 vaccine breakthrough
Pfizer and BioNTech have announced their mRNA-based vaccine candidate for COVID-19, tested in a Phase 3 study involving 43,538 participants,
Read more
Vaccine Manufacturing and R&D Facility, Novavax, Gaithersburg, Maryland
Novavax has announced the expansion of its Gaithersburg, Maryland campus to support global vaccine development through the addition of two
Read more
Sanofi & GSK to support COVAX with 200 m adjuvanted recombinant protein-based COVID-19 vaccines
Sanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read more
Lilly to supply 300,000 vials of COVID-19 monoclonal antibody to the U.S.
Eli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read more
Moderna signs agreement to supply Qatar with mRNA COVID-19 vaccine
American biotech Moderna has signed an agreement with the Ministry of Public Health to supply Qatar with its mRNA COVID-19
Read more
AstraZeneca receives FDA authorisation to resume COVID-19 vaccine trial
AstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read more